TrialCancer immunology, immunotherapy : CII2024

Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer.

Changhee Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.